Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

This study has been terminated.
(slow enrollment)
Information provided by (Responsible Party):
Ruth He, Georgetown University Identifier:
First received: April 13, 2009
Last updated: March 23, 2014
Last verified: March 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)